Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
argenx
Biotech
J&J's phase 2 Sjögren's data support FcRn strategy
Patients who received the 15-mg/kg dose demonstrated a more than 70% improvement in the primary endpoint of a measure of organ disease severity.
James Waldron
Jun 17, 2024 8:47am
Roivant FcRn inhibitor avoids cholesterol problem, shares spike
Sep 26, 2023 10:56am
Metrodora opens neuroimmune research center in Salt Lake City
Apr 19, 2023 11:11am
Argenx, Genmab join forces to expand into new therapeutic areas
Apr 17, 2023 6:20am
UCB races to regulators after $2B rare disease bet delivers data
Feb 4, 2022 8:25am
Johnson & Johnson culls $1.6B argenx blood cancer drug collab
Jun 7, 2021 4:14am